Vimarsana
Biggest News Aggregation in the World

Page 10 - Preterm Labor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preterm Labor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preterm Labor Today - Breaking & Trending Today

ObsEva Announces Year End 2020 Financial Results and Business Update - Vimarsana News

ObsEva Announces Year End 2020 Financial Results and Business Update

ObsEva Announces Year End 2020 Financial Results and Business Update March 05, 2021 01:00 ET | Source: ObsEva SA ObsEva SA Plan-Les-Ouates Geneva, SWITZERLAND -Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study  expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maxi...

ObsEva SA: ObsEva Provides Business Outlook for 2021 - Vimarsana News

ObsEva SA: ObsEva Provides Business Outlook for 2021

ObsEva SA: ObsEva Provides Business Outlook for 2021 GENEVA, Switzerland and BOSTON, MA (February 10, 2021) - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021. "We made significant progress across all aspects of the company in 2020, most significantly preparing Yselty for uterine fibroids for regulatory approval with a filed and validated European marketing authorization application and an up...

ObsEva Provides Business Outlook for 2021 - Vimarsana News

ObsEva Provides Business Outlook for 2021

for Uterine Fibroids ObsEva is developing Yselty®, an oral GnRH receptor antagonist with the potential to treat more women thanks to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) recent validation of the marketing authorization application (MAA), a major milestone toward making Yselty® available in the E.U., the Company will continue to work closely with the EMA to achieve marketing approval, projected in Q4:2021. The second key objective for 2...

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Provides Business Outlook for 2021 - Vimarsana News

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Provides Business Outlook for 2021

ObsEva Provides Business Outlook for 2021   GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021. “We made significant progress across all aspects of the company in 2020, most significantly preparing Yselty® for uterine fibroids for regulatory approval with a filed and validated European marketing authorization application and an up...

Treating Fetus as Patient Can Reduce Preterm Birth - Vimarsana News

Treating Fetus as Patient Can Reduce Preterm Birth

Treating Fetus as Patient Can Reduce Preterm Birth by Anjanee Sharma on  January 23, 2021 at 5:42 PM Texas-based researchers pave the way for developing a new medicine delivery system that could reduce the incidence of preterm labor and premature birth by treating the fetus as the patient. Preterm labor is suspected to be triggered by inflammation caused by the fetus being sick. Researchers have proven this hypothesis by studying assumptions about the relationship between a mother and the fetus's health. Dr. Ramkumar Menon and his team tested bioengineered exosomes a...